K.J. Harrison & Partners Inc Purchases New Position in Thermo Fisher Scientific Inc. $TMO

K.J. Harrison & Partners Inc acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,898 shares of the medical research company’s stock, valued at approximately $952,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. High Note Wealth LLC lifted its holdings in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares during the last quarter. Swiss RE Ltd. acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $28,000. Legacy Wealth Managment LLC ID increased its position in Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares during the period. Birchwood Financial Partners Inc. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $29,000. Finally, Core Wealth Advisors LLC bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $30,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on TMO. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Stifel Nicolaus set a $650.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, August 5th. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Jefferies Financial Group reiterated a “buy” rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Finally, HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their price objective for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Price Performance

TMO stock opened at $590.00 on Wednesday. The company’s 50-day moving average price is $533.64 and its two-hundred day moving average price is $508.36. The firm has a market cap of $218.15 billion, a P/E ratio of 31.74, a P/E/G ratio of 2.39 and a beta of 0.84. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter last year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $71,191,194.75. This trade represents a 7.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 52,053 shares of company stock worth $30,643,589 in the last three months. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.